Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 02; 21(2):181-209.
View in:
PubMed
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors. Int J Clin Oncol. 2022 Dec; 27(12):1881-1890.
View in:
PubMed
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer. J Clin Oncol. 2023 Jan 20; 41(3):599-608.
View in:
PubMed
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer. JAMA Oncol. 2022 09 01; 8(9):1317-1322.
View in:
PubMed
A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignancies. Cancer Chemother Pharmacol. 2022 03; 89(3):423-430.
View in:
PubMed
Vulvar Yolk Sac Tumors Are Somatically Derived SMARCB1 (INI-1)-Deficient Neoplasms. Am J Surg Pathol. 2022 02 01; 46(2):169-178.
View in:
PubMed
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours. Br J Cancer. 2022 04; 126(7):1027-1036.
View in:
PubMed
Next-Generation Sequencing in the Diagnosis of Metastatic Lesions: Reclassification of a Glioblastoma as an Endometrial Cancer Metastasis to the Brain. Oncologist. 2021 12; 26(12):e2102-e2109.
View in:
PubMed
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021. J Natl Compr Canc Netw. 2021 08 01; 19(8):888-895.
View in:
PubMed
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer. Gynecol Oncol. 2021 09; 162(3):661-666.
View in:
PubMed
Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. J Clin Oncol. 2021 05 10; 39(14):1531-1539.
View in:
PubMed
Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. Gynecol Oncol. 2021 05; 161(2):581-586.
View in:
PubMed
Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2020 12; 86(6):815-827.
View in:
PubMed
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecol Oncol. 2020 10; 159(1):72-78.
View in:
PubMed
NCCN Guidelines Insights: Cervical Cancer, Version 1.2020. J Natl Compr Canc Netw. 2020 06; 18(6):660-666.
View in:
PubMed
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect. Gynecol Oncol. 2020 06; 157(3):578-584.
View in:
PubMed
Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 11 01; 17(11):1374-1391.
View in:
PubMed
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. J Clin Oncol. 2019 10 20; 37(30):2786-2794.
View in:
PubMed
Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. Gynecol Oncol. 2019 07; 154(1):95-101.
View in:
PubMed
Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. Gynecol Oncol. 2019 06; 153(3):471-478.
View in:
PubMed
Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 01; 17(1):64-84.
View in:
PubMed
Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Feb; 16(2):170-199.
View in:
PubMed
Surveillance Imaging in Patients With Endometrial Cancer in First Remission. Curr Probl Diagn Radiol. 2018 Sep; 47(5):311-316.
View in:
PubMed
Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 01; 15(1):92-120.
View in:
PubMed
Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Cancer. 2016 Nov 15; 122(21):3297-3306.
View in:
PubMed
Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. J Allergy Clin Immunol Pract. 2016 May-Jun; 4(3):497-504.
View in:
PubMed
Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. J Allergy Clin Immunol. 2016 Apr; 137(4):1154-1164.e12.
View in:
PubMed
Uterine Sarcoma, Version 1.2016: Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2015 Nov; 13(11):1321-31.
View in:
PubMed
Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother Pharmacol. 2015 Aug; 76(2):417-23.
View in:
PubMed
Cervical Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015 Apr; 13(4):395-404; quiz 404.
View in:
PubMed
Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma. Gynecol Oncol. 2014 Oct; 135(1):54-7.
View in:
PubMed
A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2014 Jun; 133(3):537-41.
View in:
PubMed
Uterine neoplasms, version 1.2014. J Natl Compr Canc Netw. 2014 Feb; 12(2):248-80.
View in:
PubMed
Pushing the bar in treatment of cervical cancer: what can comprehensive cancer centers do on their own? Gynecol Oncol. 2013 Nov; 131(2):464-6.
View in:
PubMed
Cervical cancer. J Natl Compr Canc Netw. 2013 Mar 01; 11(3):320-43.
View in:
PubMed
Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol. 2013 Apr; 129(1):63-8.
View in:
PubMed
Securing discharge follow-up appointments in a women's cancer program. J Clin Oncol. 2012 Dec; 30(34_suppl):81.
View in:
PubMed
A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol. 2013 Feb; 128(2):215-20.
View in:
PubMed
Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy. Gynecol Oncol. 2012 Oct; 127(1):51-4.
View in:
PubMed
Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):41-6.
View in:
PubMed
Antimitotic inhibitors. Hematol Oncol Clin North Am. 2012 Jun; 26(3):607-28, viii-ix.
View in:
PubMed
Bevacizumab rechallenge after first line maintenance bevacizumab. Gynecol Oncol. 2012 May; 125(2):510-1.
View in:
PubMed
Young women diagnosed with early-stage ovarian cancer or borderline malignancy of the ovary: a focus on fertility and sexual function. J Psychosoc Oncol. 2012; 30(4):387-401.
View in:
PubMed
Ovarian squamous cell carcinoma arising from mature cystic teratoma. Cancer Imaging. 2011 Jun 15; 11:67-9.
View in:
PubMed
The use of bevacizumab and concurrent radiation for recurrent gynecologic cancers. J Clin Oncol. 2011 May 20; 29(15_suppl):5101.
View in:
PubMed
Patterns of recurrence in advanced epithelial ovarian, fallopian tube, and peritoneal cancers treated with intraperitoneal chemotherapy. J Clin Oncol. 2011 May 20; 29(15_suppl):5072.
View in:
PubMed
Cervical cancer. J Natl Compr Canc Netw. 2010 Dec; 8(12):1388-416.
View in:
PubMed
Cervical cancer screening. J Natl Compr Canc Netw. 2010 Dec; 8(12):1358-86.
View in:
PubMed
Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. Int J Clin Oncol. 2010 Aug; 15(4):390-8.
View in:
PubMed
A current review of targeted therapeutics for ovarian cancer. J Oncol. 2010; 2010:149362.
View in:
PubMed
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010 Jan 01; 28(1):154-9.
View in:
PubMed
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009 Nov 20; 27(33):5601-6.
View in:
PubMed
Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecol Oncol. 2009 Aug; 114(2):353-9.
View in:
PubMed
Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer. Clin Breast Cancer. 2009 May; 9(2):101-7.
View in:
PubMed
Uterine Neoplasms. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2009 May; 7(5):498-531.
View in:
PubMed
A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer. 2009 Feb; 9(1):39-44.
View in:
PubMed
VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res. 2008 Dec 01; 14(23):7871-7.
View in:
PubMed
Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 Dec 10; 26(35):5761-6.
View in:
PubMed
Anti-epidermal growth factor receptor strategies for advanced breast cancer. Cancer Invest. 2008 Oct; 26(8):757-68.
View in:
PubMed
Progress in the multidisciplinary treatment of gastrointestinal cancer and the impact on clinical practice: perioperative management of rectal cancer. Ann Oncol. 2008 Sep; 19 Suppl 7:vii266-72.
View in:
PubMed
Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008 Sep; 122(3):574-80.
View in:
PubMed
Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5523.
View in:
PubMed
Anaphylactic and anaphylactoid reactions to chemotherapy: outcomes and safety of rapid intravenous and intraperitoneal desensitizations in 413 cases. J Clin Oncol. 2008 May 20; 26(15_suppl):5526.
View in:
PubMed
Comparison of the quality of life of early and advanced stage ovarian cancer survivors. J Clin Oncol. 2008 May 20; 26(15_suppl):5528.
View in:
PubMed
Cervical cancer screening. J Natl Compr Canc Netw. 2008 Jan; 6(1):58-82.
View in:
PubMed
Anaphylactic and anaphylactoid reactions to chemotherapy: outcomes and safety of rapid intervenous and intraperitoneal desensitizations in 413 cases. 2008; 26(ASCO 2008):A:5526.
Comparison of the quality of life of early and advanced stage ovarian cancer survivors. 2008; 26(ASCO 2008):A:5528.
Cervical cancer. J Natl Compr Canc Netw. 2008 Jan; 6(1):14-36.
View in:
PubMed
Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. 2008; 26(ASCO 2008):A: 5523.
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer. 2007 Dec 17; 97(12):1618-24.
View in:
PubMed
Integrative decisions in rectal cancer. Ann Oncol. 2007 Jul; 18 Suppl 9:ix127-31.
View in:
PubMed
Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarin and mullerian cancers. 2007; 25(ASCO 2007):A:5517.
Chemotherapy and radiation therapy UPSC. 2007; 25(ASCO 2007):A:5535.
A multimodality approach to localized rectal cancer. Ann Oncol. 2006 Sep; 17 Suppl 10:x129-34.
View in:
PubMed
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen. Gynecol Oncol. 2006 Nov; 103(2):575-80.
View in:
PubMed
Phase I trial of liposomal doxorubicin and ZD 1839 in patients with refractory gynecological malignancies or metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5085.
View in:
PubMed
Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5020.
View in:
PubMed
Uterine cancers. J Natl Compr Canc Netw. 2006 May; 4(5):438-62.
View in:
PubMed
Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer. Gynecol Oncol. 2006 Oct; 103(1):160-4.
View in:
PubMed
Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced mullerian tumors. 2006; 24(ASCO 2006):A:5020.
Phase I trial of liposomal doxorubicin and ZD 1839 in patients with refractoy gynecological malignancies or metastatic breast cancer. 2006; 24(ASCO 2006):A:5085.
Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia. J Natl Compr Canc Netw. 2005 Nov; 3(6):807-16.
View in:
PubMed
A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors. Int J Gynecol Cancer. 2005 Nov-Dec; 15(6):1035-41.
View in:
PubMed
Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol. 2005 Aug 20; 23(24):5597-604.
View in:
PubMed
A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours. Br J Cancer. 2005 Jul 11; 93(1):54-9.
View in:
PubMed
Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res. 2005 Jun 15; 11(12):4430-6.
View in:
PubMed
Rapid inpatient and outpatient desensitization for carboplatin or paclitaxel hypersensitivity: A protocol effective in patients with gynecologic malignancies. J Clin Oncol. 2005 Jun; 23(16_suppl):5090.
View in:
PubMed
A phase II trial of modified triple doublets for the treatment of advanced Müllerian malignancies. J Clin Oncol. 2005 Jun; 23(16_suppl):5010.
View in:
PubMed
Activity of oral irinotecan (IRI) in metastatic breast cancer (MBC) patients after prior anthracycline, taxane and capecitabine: Phase 2 study results. J Clin Oncol. 2005 Jun; 23(16_suppl):562.
View in:
PubMed
Long-acting octreotide for the treatment of symptoms of bowel obstruction in advanced ovarian cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):5159.
View in:
PubMed
A phase II trial of modified triple doublets for the treatment of advanced Mullerian malignancies. 2005; 23(ASCO 2005):A:5010.
Long-acting octreotide (Sandostatin LAR Depot) for the treatment of symptoms of bowel obstruction in advanced ovarian cancer. 2005; 23(ASCO 2005):A:5191.
Activity of oral irinotecan (IRI) in metastatic breast cancer (MBC) patients after prior anthracycline, taxane and capecitabine: Phase 2 study results. 2005; 23(ASCO 2005):A:562.
Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol. 2005 Jan; 96(1):10-8.
View in:
PubMed
Rapid inpatient and outpatient desensitization for carboplatin or paclitaxel hypersensitivity: a protocol effective in patients with gynecological malignancies. 2005; 23(ASCO 2005):A:5090.
Evolving treatment approaches for early breast cancer. Breast Cancer Res Treat. 2005; 89 Suppl 1:S1-7.
View in:
PubMed
A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer. Gynecol Oncol. 2005 Jan; 96(1):198-203.
View in:
PubMed
Cervical cancer guidelines. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2004 Nov; 2(6):612-30.
View in:
PubMed
Cervical cancer screening clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2004 Nov; 2(6):570-87.
View in:
PubMed
A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy. J Clin Oncol. 2004 Jul 15; 22(14_suppl):5054.
View in:
PubMed
A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral disease. J Clin Oncol. 2004 Jul 15; 22(14_suppl):628.
View in:
PubMed
A phase II study of fixed dose-rate gemcitabine in patients with relapsed Müllerian tumors. J Clin Oncol. 2004 Jul 15; 22(14_suppl):5151.
View in:
PubMed
Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies. Gynecol Oncol. 2004 Jun; 93(3):702-7.
View in:
PubMed
A phase II study of fixed dose-rate gemcitabine in patients with relapsed Mullerian tumors. 2004; 22(ASCO 2004):A:5151.
A comparative study of exemestane versus anastroxole in post-metopausal breast cancer subjects aith visceral disease. 2004; 22(ASCO 2004):A:628.
Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist. 2004; 9(2):126-36.
View in:
PubMed
A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy. 2004; 22(ASCO 2004):A:5054.
Phase II trial of anastrozole in women with asymptomatic müllerian cancer. Gynecol Oncol. 2003 Dec; 91(3):596-602.
View in:
PubMed
A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies. Gynecol Oncol. 2003 Nov; 91(2):293-8.
View in:
PubMed
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003 Aug 01; 21(15):2889-95.
View in:
PubMed
Phase I study of cisplatin and gemcitabine for recurrent cervix cancer following primary radiotherapy or newly diagnosed metastatic cervix cancer. 2003; 22(ASCO 2003):A:1872.
Epoetin alfa 40,000 u once weekly significantly improves hemoglobin and quality of life in anemic patients with ovarian cancer. 2003; 22(ASCO 2003):A:3111.
Hormonal therapy in postmenopausal women with breast cancer. Oncology. 2003; 64(4):289-99.
View in:
PubMed
Liposomal anthracyclines: adjuvant and neoadjuvant therapy for breast cancer. Oncologist. 2003; 8 Suppl 2:10-6.
View in:
PubMed
A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol. 2002 Sep; 86(3):302-10.
View in:
PubMed
The impact of anemia and its treatment on patients with gynecologic malignancies. Semin Oncol. 2002 Jun; 29(3 Suppl 8):7-12.
View in:
PubMed
Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol. 2002 Mar 15; 20(6):1562-9.
View in:
PubMed
TLC D99 (D,Myocet) Herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis. 2002; 21(ASCO 2002):A:216.
Multicenter phase II study of trastuzumab (Herceptin;H) and vinorelbine (Navelbine;N) as first-line therapy for HER2 overexpressing metastic breast cancer (HER2+MBC). 2002; 21(ASCO 2002):A:211.
A phase I of vaccination with lethally irradiated, autologous ovarian cancer cells engineered by adenoviral mediated gene transfer to secrete human granulocyte-macrophage colony stimulating factor (GVAX). 2002; 21(ASCO 2002):A:1840.
A phase I trial of continual sequential oral etoposide and infusional topotecan. 2002; 21(ASCO2002):A:2168.
A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. Cancer. 2001 Sep 01; 92(5):1156-67.
View in:
PubMed
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15; 19(10):2722-30.
View in:
PubMed
The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol. 2001 May; 81(2):206-12.
View in:
PubMed
Triple Doublet Chemotherapy for the Treatment of Mullerian Malignancies. 2001; 20(ASCO 2001):A:846.
Preliminary Cardiac Safety and Efficacy Data from Phase I/II Trial of TLC D-99 (D-99) and Trastuzumab (T) in patients withs locally advanced or Metastatic Breast CAncer (LABC/MBC). 2001; 20(ASCO 2001):A:180.
A Phase II and Pharmacokinetic/Dynamic study of Doxil and weekly Paclitaxel chemotherapy for Rucurrent Mullerian Tumors. 2001; 20(ASCO 2001):A:2524.
A Phase II and Pharmacokinetic/Dynamic Studyof Doxil and Weekly Paclitaxel Chemotherapy for Recurrent Mullerian Tumors. 2000; 19(ASCO 2000):A:1623.
A Phase I/II Pharmacokinetic Study of 96-Hour Infusional Topotecan and Paclitaxel Chemotherapy for Recuurent Mullerian Tumors. 2000; 19(ASCO 2000):A:1552.
Herceptin and Vinorelbine for HER-2 Positive Metastatic Breast Cancer: A Phase II Study. 2000; 19(ASCO 2000):A:392.
Phase I Study Cisplatin and Gemcitabine for Recurrent Cervix Cancer Following Primary Radiotherapy. 2000; 19(ASCO 2000):A:1571.
A Phase I Study Cyclophosphamide, Doxorubicin, and Eniluracil/5-FU in Women with Advanced Breast Cancer: Preliminary Results. 2000; 19(ASCO 2000):A:444.
Magnetic resonance angiography in the diagnosis of a case of giant cell arteritis manifesting as scalp necrosis. Arch Dermatol. 1999 Jul; 135(7):769-71.
View in:
PubMed
A Retrospective Analysis of the Clinical Utility of Doxil in Recurrent Ovarian Cancer(ROC)(Meeting abstract). 1999; (ASCO 1999):A:1434.
Images in clinical medicine. Spigelian hernia. N Engl J Med. 1997 Apr 17; 336(16):1149.
View in:
PubMed